Insight Molecular Diagnostics Inc. (IMDX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 4.3 |
| Open | 4.37 |
| Day High | 4.45 |
| Day Low | 4.32 |
| 52-Week High | 8.51 |
| 52-Week Low | 2.33 |
| Volume | 38,690 |
| Average Volume | 233,920 |
| Market Cap | 140.14M |
| PE | -2.91 |
| EPS | -1.49 |
| Moving Average 50 Days | 4.94 |
| Moving Average 200 Days | 5.39 |
| Change | 0.04 |
Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission
GlobeNewswire Inc.
Mar 03, 2026 1:00 PM GMT
Three-site reproducibility study completed by Tampa General Hospital, Mayo Clinic, and Baylor Scott & White HealthSufficient clinical samples collected to support statistical analysis and FDA submissionCompany achieved final ISO 13485 certification o
iMDx Announces $26.0 Million Registered Direct Offering
GlobeNewswire Inc.
Feb 11, 2026 1:00 PM GMT
NASHVILLE, Tenn., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (“iMDx” or the “Company”), today announced that it has entered into definitive agreements with certain institutional investors for the purchase
IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring
GlobeNewswire Inc.
Jan 13, 2026 2:00 PM GMT
American Journal of Transplantation position paper also highlights value of absolute quantification of dd-cfDNA as a diagnostic marker, a key feature of iMDx’s flagship GraftAssureTM family of assays NASHVILLE, Tenn., Jan. 13, 2026 (GLOBE NEWSWIRE)